The London COPD exacerbation (EXCEL) cohort builds on an established cohort started in 1995 and designed to study COPD exacerbations and their impact on health-status and disease progression.
Our intentions are to phenotype Chronic Obstructive Pulmonary Disease (COPD) patients on the basis of factors that a related to (a) exacerbation frequency which will include (b) lung function to assess disease severity, (c) baseline therapy, (d) airway and systemic inflammatory markers, (e) health status, (f) gene expression, (g) airway bacterial and viral load and (h) co-morbidity including cardiovascular disease, diabetes and psychological disease, (i) psychological factors,(j) mortality, (k) nasal susceptibility to rhinovirus infection, (l) heart rate variability (m) exhaled hydrogen sulphide.
Study Type
OBSERVATIONAL
Enrollment
300
National Heart and Lung Institute, Imperial College
London, United Kingdom
RECRUITINGAnnual exacerbation rate (number of exacerbations over a 12 month period)
Definition of an exacerbation * The presence of 2 new symptoms (one of which must be major) for 2 consecutive days * Major symptoms: increased breathlessness (A), increased sputum colour (B1) or increased sputum amount (B2) * Minor symptoms: a cold (C), increased wheeze or chest tightness (D), Sore throat (E1), Increased cough (E2), Fever (F)
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.